TISIDB

Summary
Symbol	CBX8
Name	chromobox homolog 8
Aliases	RC1; HPC3; polycomb 3; Pc class 3 homolog (Drosophila); chromobox homolog 8 (Drosophila Pc class); Pc class ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF17218 CBX family C-terminal motif PF00385 Chromo (CHRromatin Organisation MOdifier) domain
Function	Component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A 'Lys-119', rendering chromatin heritably changed in its expressibility.

> Gene Ontology [ TOP ]
Biological Process	GO:0000302 response to reactive oxygen species GO:0006282 regulation of DNA repair GO:0006979 response to oxidative stress GO:0010035 response to inorganic substance GO:0010712 regulation of collagen metabolic process GO:0010714 positive regulation of collagen metabolic process GO:0016570 histone modification GO:0016574 histone ubiquitination GO:0016925 protein sumoylation GO:0018205 peptidyl-lysine modification GO:0032963 collagen metabolic process GO:0032964 collagen biosynthetic process GO:0032965 regulation of collagen biosynthetic process GO:0032967 positive regulation of collagen biosynthetic process GO:0034599 cellular response to oxidative stress GO:0034614 cellular response to reactive oxygen species GO:0042542 response to hydrogen peroxide GO:0044236 multicellular organism metabolic process GO:0044246 regulation of multicellular organismal metabolic process GO:0044253 positive regulation of multicellular organismal metabolic process GO:0044259 multicellular organismal macromolecule metabolic process GO:0045739 positive regulation of DNA repair GO:0051052 regulation of DNA metabolic process GO:0051054 positive regulation of DNA metabolic process GO:0070301 cellular response to hydrogen peroxide GO:2001020 regulation of response to DNA damage stimulus GO:2001022 positive regulation of response to DNA damage stimulus
Molecular Function	GO:0003727 single-stranded RNA binding GO:0035064 methylated histone binding GO:0042393 histone binding GO:0055103 ligase regulator activity GO:0055106 ubiquitin-protein transferase regulator activity GO:0097027 ubiquitin-protein transferase activator activity
Cellular Component	GO:0000151 ubiquitin ligase complex GO:0000152 nuclear ubiquitin ligase complex GO:0000785 chromatin GO:0000790 nuclear chromatin GO:0000792 heterochromatin GO:0031519 PcG protein complex GO:0035102 PRC1 complex GO:0044454 nuclear chromosome part

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-2559583: Cellular Senescence R-HSA-2262752: Cellular responses to stress R-HSA-392499: Metabolism of proteins R-HSA-2559580: Oxidative Stress Induced Senescence R-HSA-597592: Post-translational protein modification R-HSA-3108232: SUMO E3 ligases SUMOylate target proteins R-HSA-2990846: SUMOylation R-HSA-3108214: SUMOylation of DNA damage response and repair proteins R-HSA-4570464: SUMOylation of RNA binding proteins

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-392499: Metabolism of proteins
R-HSA-2559580: Oxidative Stress Induced Senescence
R-HSA-597592: Post-translational protein modification
R-HSA-3108232: SUMO E3 ligases SUMOylate target proteins
R-HSA-2990846: SUMOylation
R-HSA-3108214: SUMOylation of DNA damage response and repair proteins
R-HSA-4570464: SUMOylation of RNA binding proteins

Summary
Symbol	CBX8
Name	chromobox homolog 8
Aliases	RC1; HPC3; polycomb 3; Pc class 3 homolog (Drosophila); chromobox homolog 8 (Drosophila Pc class); Pc class ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CBX8 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between CBX8 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
27505670	Diffuse Large B Cell Lymphoma	Inhibit immunity	Herein we show that the actions of EZH2 in driving GC formation and lymphoma precursor lesions require site-specific binding by the BCL6 transcriptional repressor and the presence of a non-canonical PRC1-BCOR-CBX8 complex. The chromodomain protein CBX8 is induced in GC B cells, binds to H3K27me3 at bivalent promoters, and is required for stable association of the complex and the resulting histone modifications. Moreover, oncogenic BCL6 and EZH2 cooperate to accelerate diffuse large B cell lymphoma (DLBCL) development and combinatorial targeting of these repressors results in enhanced anti-lymphoma activity in DLBCLs.

Summary
Symbol	CBX8
Name	chromobox homolog 8
Aliases	RC1; HPC3; polycomb 3; Pc class 3 homolog (Drosophila); chromobox homolog 8 (Drosophila Pc class); Pc class ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CBX8 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CBX8
Name	chromobox homolog 8
Aliases	RC1; HPC3; polycomb 3; Pc class 3 homolog (Drosophila); chromobox homolog 8 (Drosophila Pc class); Pc class ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CBX8 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.375	0.323
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.726	0.666
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.128	0.928
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.014	0.972
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.277	0.852
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.384	0.829
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.044	0.901
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.537	0.559
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.652	0.533
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.354	0.653
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.154	0.879
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.184	0.0406

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CBX8 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	CBX8
Name	chromobox homolog 8
Aliases	RC1; HPC3; polycomb 3; Pc class 3 homolog (Drosophila); chromobox homolog 8 (Drosophila Pc class); Pc class ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CBX8. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CBX8
Name	chromobox homolog 8
Aliases	RC1; HPC3; polycomb 3; Pc class 3 homolog (Drosophila); chromobox homolog 8 (Drosophila Pc class); Pc class ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CBX8. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CBX8. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CBX8
Name	chromobox homolog 8
Aliases	RC1; HPC3; polycomb 3; Pc class 3 homolog (Drosophila); chromobox homolog 8 (Drosophila Pc class); Pc class ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CBX8. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CBX8
Name	chromobox homolog 8
Aliases	RC1; HPC3; polycomb 3; Pc class 3 homolog (Drosophila); chromobox homolog 8 (Drosophila Pc class); Pc class ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CBX8 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CBX8
Name	chromobox homolog 8
Aliases	RC1; HPC3; polycomb 3; Pc class 3 homolog (Drosophila); chromobox homolog 8 (Drosophila Pc class); Pc class ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CBX8 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CBX8
Name	chromobox homolog 8
Aliases	RC1; HPC3; polycomb 3; Pc class 3 homolog (Drosophila); chromobox homolog 8 (Drosophila Pc class); Pc class ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CBX8 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CBX8